WST
West Pharmaceutical Services, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Strong buy
+59/100
Last price
372.29
▼ 4.47 (1.19%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
378.00
Prev close
376.76
Day high
381.16
Day low
367.64
Volume
401.40K
Market cap
$26.22B
P/E (TTM)
47.71
52W range
223.83 – 386.00
Day trading desk
Gap from prior close
+0.33%
Prior close 376.76
VWAP
372.98
-0.18% from price
Relative volume
1.03×
Normal
Session range
3.68%
367.64 – 381.16
Position in range
34%
Mid range
ATR (14D)
8.85
2.38% of price
Prior day high
377.06
PDH
Prior day low
363.16
PDL
Bid / ask spread
—
Quote not published
Session volume
653.70K
Avg 636.49K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.06%
-3.0%
1M
+9.61%
+8.5%
3M
+5.36%
+0.8%
6M
+43.68%
+25.5%
YTD
+35.44%
+21.2%
1Y
+36.72%
+20.3%
3Y
-0.68%
-82.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on WST open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.83K
Net buying
Buy transactions
16
35.20K shares
Sell transactions
4
19.37K shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
461.67K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | FAVORITE ANNETTE F Officer |
SELL | 7.52K | $2.67M | Direct |
| Sep 15, 26 | FAVORITE ANNETTE F Officer |
CONVERSION | 7.52K | $674.45K | Direct |
| Sep 8, 26 | FAVORITE ANNETTE F Officer |
SELL | 8.13K | $2.77M | Direct |
| Sep 8, 26 | FAVORITE ANNETTE F Officer |
CONVERSION | 8.13K | $694.45K | Direct |
| Aug 11, 26 | MCMAHON ROBERT W Chief Financial Officer |
— | 7.15K | — | Direct |
| May 12, 26 | CAMPBELL SHANE ALDEN Officer |
— | 769 | — | Direct |
| May 4, 26 | BUTHMAN MARK A Director |
STOCK | 791 | $0 | Direct |
| May 4, 26 | MICHELS DOUGLAS A Director |
STOCK | 791 | $0 | Direct |
| May 4, 26 | LAI-GOLDMAN MYLA P Director |
STOCK | 791 | $0 | Direct |
| May 4, 26 | FRIEL ROBERT F Director |
STOCK | 791 | $0 | Direct |
| May 4, 26 | HAUGEN JANET BRUTSCHEA Director |
STOCK | 791 | $0 | Direct |
| May 4, 26 | FEEHERY WILLIAM F. Director |
STOCK | 791 | $0 | Direct |
| May 4, 26 | PUCCI PAOLO Director |
STOCK | 791 | $0 | Direct |
| May 4, 26 | KELLER DEBORAH L Director |
STOCK | 791 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BIRKETT BERNARD JOHN |
Chief Financial Officer | 7.52K | Conversion of Exercise of derivative security |
BUTHMAN MARK A |
Director | 44.31K | Stock Award(Grant) |
FAVORITE ANNETTE F |
Officer | 21.82K | Sale |
FEEHERY WILLIAM F. |
Director | 32.52K | Stock Award(Grant) |
GREEN ERIC MARK |
Chief Executive Officer | 175.42K | Conversion of Exercise of derivative security |
HOFMANN THOMAS W |
Director | 44.64K | Stock Award(Grant) |
KELLER DEBORAH L |
Director | 11.56K | Stock Award(Grant) |
LAI-GOLDMAN MYLA P |
Director | 20.43K | Stock Award(Grant) |
MICHELS DOUGLAS A |
Director | 46.49K | Stock Award(Grant) |
PUCCI PAOLO |
Director | 11.85K | Stock Award(Grant) |
Fundamentals
Market cap$26.22B
Enterprise value$26.11B
Revenue (TTM)$3.33B
Gross profit$1.22B
EBITDA$912.20M
Net income$564.90M
EPS (TTM)$7.81
Free cash flow$277.94M
Total cash$435.80M
Total debt$316.50M
Book value / share$42.47
Shares outstanding70.38M
Float69.85M
Short % of float3.95%
Dividend yield0.23%
Beta (5Y)1.13
Valuation & profitability ratios
Trailing P/E47.71
Forward P/E37.34
PEG ratio2.93
Price / sales—
Price / book8.77
EV / revenue7.85
EV / EBITDA28.62
Gross margin36.79%
Operating margin22.47%
Profit margin16.98%
Return on equity19.09%
Return on assets11.38%
Debt / equity10.59
Current ratio2.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.07B | $2.89B | $2.95B | $2.89B | +6.3% |
| Operating revenue | $3.07B | $2.89B | $2.95B | $2.89B | +6.3% |
| Cost of revenue | $1.97B | $1.89B | $1.82B | $1.75B | +4.0% |
| Gross profit | $1.10B | $998.50M | $1.13B | $1.14B | +10.6% |
| Research & development | $74.30M | $69.10M | $68.40M | $58.50M | +7.5% |
| Selling, general & admin | $393.60M | $338.50M | $353.40M | $316.90M | +16.3% |
| Total operating expense | $467.90M | $407.60M | $421.80M | $375.40M | +14.8% |
| Operating income | $636.10M | $590.90M | $707.40M | $760.80M | +7.6% |
| Net interest income | $17.00M | $16.60M | $19.00M | -$2.80M | +2.4% |
| Pre-tax income | $600.90M | $585.50M | $698.00M | $679.90M | +2.6% |
| Tax provision | $121.60M | $107.50M | $122.30M | $114.70M | +13.1% |
| Net income | $493.70M | $492.70M | $593.40M | $585.90M | +0.2% |
| Net income to common | $493.70M | $492.70M | $593.40M | $585.90M | +0.2% |
| Basic EPS | 6.83 | 6.75 | 7.98 | 7.87 | +1.2% |
| Diluted EPS | 6.79 | 6.69 | 7.88 | 7.73 | +1.5% |
| EBIT | $601.40M | $588.50M | $707.00M | $687.80M | +2.2% |
| EBITDA | $772.80M | $743.90M | $844.30M | $808.40M | +3.9% |
| Basic shares | 72.30M | 73.00M | 74.30M | 74.40M | -1.0% |
| Diluted shares | 72.70M | 73.70M | 75.30M | 75.80M | -1.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $791.30M | $484.60M | $853.90M | $894.30M | — | +63.3% |
| Cash & short-term investments | $791.30M | $484.60M | $853.90M | $894.30M | — | +63.3% |
| Accounts receivable | $574.40M | $552.50M | $512.00M | $507.40M | — | +4.0% |
| Inventory | $443.90M | $377.00M | $434.70M | $414.80M | — | +17.7% |
| Total current assets | $1.98B | $1.54B | $1.94B | $1.92B | — | +28.6% |
| Property, plant & equipment | $1.84B | $1.69B | $1.51B | $1.26B | — | +9.3% |
| Goodwill & intangibles | $117.70M | $116.90M | $123.60M | $125.70M | — | +0.7% |
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | — | +17.2% |
| Total current liabilities | $654.90M | $550.40M | $671.80M | $519.00M | — | +19.0% |
| Current debt | — | — | $134.00M | $2.20M | $44.20M | — |
| Long-term debt | $202.80M | $202.60M | $72.80M | $206.70M | — | +0.1% |
| Total debt | $321.10M | $302.30M | $309.00M | $317.90M | — | +6.2% |
| Total liabilities | $1.09B | $961.10M | $948.50M | $931.90M | — | +13.8% |
| Retained earnings | $4.37B | $3.96B | $3.52B | $2.99B | — | +10.6% |
| Shareholder equity | $3.18B | $2.68B | $2.88B | $2.68B | — | +18.4% |
| Working capital | $1.32B | $987.70M | $1.26B | $1.40B | — | +34.0% |
| Net tangible assets | $3.06B | $2.57B | $2.76B | $2.56B | — | +19.2% |
| Shares issued | 75.34M | 75.30M | 75.30M | 75.30M | — | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $493.70M | $492.70M | $593.40M | $585.90M | +0.2% |
| Depreciation & amortisation | $171.40M | $155.40M | $137.30M | $120.60M | +10.3% |
| Stock-based compensation | $23.80M | $18.70M | $23.30M | $23.70M | +27.3% |
| Change in working capital | $79.80M | $2.90M | -$20.40M | -$15.00M | +2,651.7% |
| Operating cash flow | $754.80M | $653.40M | $776.50M | $724.00M | +15.5% |
| Capital expenditure | -$285.90M | -$377.00M | -$362.00M | -$284.60M | +24.2% |
| Investing cash flow | -$285.90M | -$378.70M | -$368.70M | -$288.20M | +24.5% |
| Share buybacks | -$136.80M | -$566.60M | -$451.20M | -$222.20M | +75.9% |
| Dividends paid | -$61.20M | -$59.10M | -$57.00M | -$54.10M | -3.6% |
| Financing cash flow | -$185.10M | -$622.60M | -$459.60M | -$293.60M | +70.3% |
| Free cash flow | $468.90M | $276.40M | $414.50M | $439.40M | +69.6% |
| End cash position | $791.30M | $484.60M | $853.90M | $894.30M | +63.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $872.30M | $844.90M | $805.00M | $804.60M | $766.50M | +3.2% |
| Operating revenue | $872.30M | $844.90M | $805.00M | $804.60M | $766.50M | +3.2% |
| Cost of revenue | $543.10M | $548.50M | $501.10M | $510.30M | $492.60M | -1.0% |
| Gross profit | $329.20M | $296.40M | $303.90M | $294.30M | $273.90M | +11.1% |
| Research & development | $19.70M | $15.80M | $21.80M | $17.10M | $19.10M | +24.7% |
| Selling, general & admin | $117.60M | $99.50M | $107.00M | $102.70M | $95.90M | +18.2% |
| Total operating expense | $137.30M | $115.30M | $128.80M | $119.80M | $115.00M | +19.1% |
| Operating income | $191.90M | $181.10M | $175.10M | $174.50M | $158.90M | +6.0% |
| Net interest income | $1.20M | $3.20M | $5.30M | $4.50M | $3.50M | -62.5% |
| Pre-tax income | $180.10M | $180.10M | $161.50M | $171.90M | $157.00M | 0.0% |
| Tax provision | $32.20M | $44.70M | $33.30M | $34.00M | $30.20M | -28.0% |
| Net income | $154.00M | $138.80M | $132.10M | $140.00M | $131.80M | +11.0% |
| Net income to common | $154.00M | $138.80M | $132.10M | $140.00M | $131.80M | +11.0% |
| Basic EPS | 2.17 | 1.93 | 1.83 | 1.94 | 1.82 | +12.4% |
| Diluted EPS | 2.15 | 1.92 | 1.82 | 1.92 | 1.82 | +12.0% |
| EBIT | $182.70M | $182.00M | $161.30M | $172.10M | $157.10M | +0.4% |
| EBITDA | $228.90M | $227.20M | $208.30M | $215.10M | $198.50M | +0.7% |
| Basic shares | 70.80M | 72.00M | 72.30M | 72.20M | 72.20M | -1.7% |
| Diluted shares | 71.30M | 72.40M | 72.70M | 72.60M | 72.50M | -1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $435.80M | $521.40M | $791.30M | $628.50M | $509.70M | -16.4% |
| Cash & short-term investments | $435.80M | $521.40M | $791.30M | $628.50M | $509.70M | -16.4% |
| Accounts receivable | $712.00M | $685.60M | $574.40M | $625.00M | $582.40M | +3.9% |
| Inventory | $447.40M | $452.60M | $443.90M | $438.00M | $421.10M | -1.1% |
| Total current assets | $1.81B | $1.83B | $1.98B | $1.82B | $1.68B | -1.1% |
| Property, plant & equipment | $1.79B | $1.81B | $1.84B | $1.84B | $1.83B | -1.2% |
| Goodwill & intangibles | $115.10M | $116.20M | $117.70M | $119.50M | $120.60M | -0.9% |
| Total assets | $4.08B | $4.11B | $4.27B | $4.11B | $3.95B | -0.8% |
| Total current liabilities | $640.50M | $674.00M | $654.90M | $635.40M | $604.60M | -5.0% |
| Long-term debt | $202.90M | $202.80M | $202.80M | $202.70M | $202.60M | +0.0% |
| Total debt | $312.10M | $316.20M | $321.10M | $297.60M | $303.30M | -1.3% |
| Total liabilities | $1.09B | $1.12B | $1.09B | $1.05B | $1.02B | -3.0% |
| Retained earnings | $4.62B | $4.48B | $4.37B | $4.26B | $4.14B | +3.3% |
| Shareholder equity | $2.99B | $2.99B | $3.18B | $3.05B | $2.93B | -0.0% |
| Working capital | $1.17B | $1.15B | $1.32B | $1.19B | $1.08B | +1.2% |
| Net tangible assets | $2.88B | $2.87B | $3.06B | $2.93B | $2.81B | +0.0% |
| Shares issued | 70.40M | 75.30M | 75.34M | 75.31M | 75.30M | -6.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $154.00M | $138.80M | $132.10M | $140.00M | $131.80M | +11.0% |
| Depreciation & amortisation | $46.20M | $45.20M | $47.00M | $43.00M | $41.40M | +2.2% |
| Stock-based compensation | $10.90M | $6.60M | $6.70M | $8.40M | $7.40M | +65.2% |
| Change in working capital | -$86.00M | -$102.90M | $81.70M | $2.10M | -$4.10M | +16.4% |
| Operating cash flow | $124.00M | $89.90M | $251.10M | $197.20M | $177.10M | +37.9% |
| Capital expenditure | -$43.20M | -$42.70M | -$76.10M | -$63.30M | -$75.20M | -1.2% |
| Investing cash flow | -$43.20M | -$42.70M | -$76.10M | -$63.30M | -$75.20M | -1.2% |
| Share buybacks | -$156.70M | -$300.10M | -$200.00K | -$100.00K | -$500.00K | +47.8% |
| Dividends paid | -$15.70M | -$15.80M | -$15.80M | -$15.10M | -$15.10M | +0.6% |
| Financing cash flow | -$164.80M | -$308.70M | -$11.70M | -$11.50M | -$14.90M | +46.6% |
| Free cash flow | $80.80M | $47.20M | $175.00M | $133.90M | $101.90M | +71.2% |
| End cash position | $435.80M | $521.40M | $791.30M | $628.50M | $509.70M | -16.4% |
Options analytics
Put / call volume
0.32
Call-heavy session
Put / call open interest
0.17
Positioning, not flow
Max pain
360.00
-3.4% from spot
ATM implied vol
30.2%
Nearest strike to spot
Skew (10% OTM)
+0.5%
Puts bid over calls
Call volume
110
Contracts, this expiry
Put volume
35
Contracts, this expiry
Heaviest call OI
390.00
303 contracts
Heaviest put OI
340.00
46 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.08 | 2.37 | +13.9% |
| Mar 2026 | 1.68 | 2.13 | +27.1% |
| Dec 2025 | 1.83 | 2.04 | +11.5% |
| Sep 2025 | 1.71 | 1.96 | +14.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.20 | 14 | $826.58M | +2.7% |
| Next quarter | 2.27 | 12 | $826.88M | +2.7% |
| Current year | 8.96 | 17 | $3.38B | +9.8% |
| Next year | 9.99 | 17 | $3.59B | +6.3% |
Analyst targets & ownership
Mean target$411.00
High target$459.00
Low target$340.00
Implied upside10.40%
Analyst count16
ConsensusSTRONG BUY
Strong buy / Buy4 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders0.66%
Held by institutions101.94%
Institutions holding1.21K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
372.23
+0.02% from price
SMA 20
364.69
+2.18% from price
SMA 50
353.63
+5.38% from price
SMA 100
344.47
+8.08% from price
SMA 200
303.39
+22.83% from price
EMA 12
369.15
+0.85% from price
EMA 26
363.04
+2.55% from price
EMA 50
355.75
+4.65% from price
RSI (14)
58.7
Neutral
MACD (12,26,9)
6.11
Hist 0.04
ATR (14)
8.85
2.37% of price
Realised vol 30D
23.0%
Annualised
Bollinger upper
386.74
20, 2σ
Bollinger lower
342.64
20, 2σ
50 / 200 cross
Golden
353.63 vs 303.39
Trend bias
Above 200
+22.83%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.59
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
23.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-24.8%
Peak to trough
Max drawdown 5Y
-59.6%
Peak to trough
ATR 14
8.85
2.37% of price
Beta (reported)
1.13
5Y monthly, from filing
Short interest
Shares short
2.38M
Prior 2.12M
Change vs prior
+12.0%
Shorts adding
% of float
3.95%
Normal
% of shares out
3.38%
Against total outstanding
Days to cover
4.9
Liquid
Float
69.85M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 26 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Sep 9, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 3, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 27, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jul 13, 26 | BNP Paribas | INITIATED | — | Outperform |
| Jul 9, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jul 2, 26 | Keybanc | MAINTAINED | Overweight | Overweight |
| Jun 9, 26 | Barclays | UPGRADE | Equal-Weight | Overweight |
| Jun 2, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| May 29, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 27, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
Dividends & splits
Forward rate$0.88 / yr
Forward yield0.23%
5-year avg yield0.24%
Payout ratio11.14%
Ex-dividend dateJul 29, 2026
Next pay dateAug 5, 2026
Last split2:1
Split dateSep 27, 2013
SEC filings
Periodic Financial Reports
10-Q · 2026-07-23
Corporate Changes & Voting Matters
8-K · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-06-01
Corporate Changes & Voting Matters
8-K/A · 2026-05-20
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-05
Corporate Changes & Voting Matters
8-K · 2026-04-23
Headlines
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Zacks · 14h ago
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal
Zacks · 14h ago
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now
Zacks · 14h ago
Barclays Raises West Pharmaceutical Services Price Target to $440 From $400, Maintains Overweight Rating
MT Newswires · 16h ago
Reasons to Retain Doximity Stock in Your Portfolio for Now
Zacks · 2d ago
Veeva's OpenData to Help Servier Build a Global AI Data Foundation
Zacks · 2d ago
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation
Zacks · 2d ago
What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report
Barchart · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.